Lipid and biomarker differences between Raltegravir and Atazanavir/Ritonavir at 48 Weeks in the Raltegravir Atazanavir Naïve (RAN) study

Tanvir Bell, Martine Diez, Xiaoying Yu, Chi Nguyen, Claudia Kozinetz

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Lipid and biomarker differences between Raltegravir and Atazanavir/Ritonavir at 48 Weeks in the Raltegravir Atazanavir Naïve (RAN) study'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology